---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-010854"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2023-08-15T23:59:59+00:00"
generated_at: "2026-06-11T09:44:52.104921+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Tenax Therapeutics amends bylaws to lower quorum to one-third, allow director removal without cause

## Summary
- Quorum for stockholder meetings reduced to one-third of shares entitled to vote from previous higher threshold.
- Directors may now be removed with or without cause by majority vote of stockholders.
- Amended bylaws add provisions clarifying mechanics for adjourning stockholder meetings.
- Other ministerial, clarifying and conforming changes were included in the Fourth Amended and Restated Bylaws.

## SEC filing metadata
- accession: 0001654954-23-010854
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2023-08-15T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000165495423010854/0001654954-23-010854-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000165495423010854/tenx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-010854
- JSON: https://secwatch.observer/filing/0001654954-23-010854.json
- Plain text: https://secwatch.observer/filing/0001654954-23-010854.txt

## Key facts
- Governance Changes
  TENAX THERAPEUTICS, INC.: Amended and restated bylaws effective August 9, 2023, including changes to quorum for stockholder meetings, adjournment mechanics, and director removal provisions (effective 2023-08-09).
  - Change: bylaw amendment
  - Effective: 2023-08-09
  source text: On August 9, 2023, the Board of Directors of Tenax Therapeutics, Inc. (the “Company”) approved the Company’s Fourth Amended and Restated Bylaws, effective immediately upon approval by the Board (the “Amended and Restated Bylaws”). The amendments enacted by the Amended and Restated Bylaws, among other things: (i) amend Article II, Section 9 regarding quorum for stockholders meetings to allow for quorum to be obtained through the presence in person or by proxy of the holders of one-third of the shares entitled to vote, (ii) add a provision clarifying the mechanics to adjourn stockholder meetings, (iii) provide for the removal of directors with or without cause by majority vote of the stockholders, and (iv) include certain other ministerial, clarifying and conforming changes.
  evidence_url: https://www.sec.gov/Archives/edgar/data/34956/000165495423010854/0001654954-23-010854-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.